CXCR5 and non-small cell lung carcinoma: For example, a phase I clinical trial at Sun Yat-sen University evaluated anti-EGFR CAR-T cells, modified for the expression of CXCR5, in EGFR-positive patients with advanced NSCLC: among 11 patients being assessed receiving different doses, two showed a partial response, and five remained stable for eight months (280).